New AHA/ACC/ADA/ASN Guideline Unifies Cardiovascular-Kidney-Metabolic Syndrome Management

This inaugural guideline establishes CKM syndrome as an integrated clinical entity, reshaping how pharmacists stage risk and sequence SGLT2i, GLP-1-based therapy, finerenone, and RASi across heart failure and its comorbidities.

📅 Journal publication: Jun 9, 2026 · Last updated: Oct 7, 2026

★ Editor's Pick2026 AHA/ACC/ADA/ASN CKM Syndrome GuidelineAmerican Heart AssociationAmerican College of CardiologyAmerican Diabetes AssociationAmerican Society of Nephrologycardiovascular-kidney-metabolic syndromeheart failurechronic kidney diseasetype 2 diabetesobesitySGLT2 inhibitorsGLP-1 receptor agonistsfinerenonenonsteroidal MRARASiARNI Guideline: Heart Failure

Background Information

New guideline integrates cardiovascular, kidney, and metabolic care.

This guideline integrates cardiovascular, kidney, and metabolic care, providing a cohesive strategy for managing these interrelated conditions. Updates from the 2013 guideline include expanded recommendations for managing obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. Aimed at a broad range of clinicians, it offers updated, evidence-based strategies to improve patient outcomes across these syndromes. Comprehensive management of cardiovascular-kidney-metabolic syndrome is crucial for improved patient outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

View on PubMed →

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →